At HA Tech, our Biotherapeutics division is at the forefront of innovation, actively developing a range of biologics. Among our notable advancements, we are proud to announce the development of biosimilar products including Insulin Glargine, Aspart, Degludec, and Semaglutide.

As we strive to enhance patient care through our commitment to scientific excellence, we are excited to share that we anticipate receiving regulatory approval for our first biological product, Insulin Glargine, by the end of 2025. At HA TECH we strive to:

• Deliver quality products to improve patient outcomes and advance the potential of modern healthcare.

• Advance the treatment of diabetes through the development of innovative and biosimilar antidiabetic drugs

• Address the shortfalls in supply for globally dependent medications.

• Combine cutting-edge research, state-of-the-art manufacturing, and rigorous clinical testing to create effective, safe, and accessible solutions for patients worldwide.